However, this mechanism is reminiscent of how the cancer drug Gleevec achieves 3000-fold selectivity for Abl over Src, despite the fact that the two proteins share ~46 % sequence identity across the kinase domain, and ~86 % identity in the Gleevec-binding site (Seeliger et al., 2007). This evidence concerns the gene SRC and cancer.